Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
Retrieved on:
Friday, May 13, 2022
VEGA, Research, U.S. Securities and Exchange Commission, LDP, Review, Risk, NDA, Diabetic retinopathy, Private Securities Litigation Reform Act, SEC, DME, Pilocarpine, Clinical trial, COVID-19, Lists of people executed in the United States, OCUP, Mitchell Jackson, GLOBE, Company, Retina, Doctor of Philosophy, Reversal, FDA, OD, Awareness, Maintenance, Optometry, Security (finance), CEO, MBA, R, Nasdaq, Patient, NASDAQ, Light, Industry, Safety, Pharmaceutical industry, Online gambling, RM, Presbyopia, Mydriasis, MD, DR, NVD
FARMINGTON HILLS, Mich., May 13, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Points:
- FARMINGTON HILLS, Mich., May 13, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
- First Quarter Ended March 31, 2022 Financial Highlights
As of March 31, 2022, Ocuphire had cash and cash equivalents of approximately $19.2 million. - The loss from operations for the quarter ended March 31, 2022 was $6.5 million, compared to $5.2 million for the quarter ended March 31, 2021.
- Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.